|

Sacituzumab Tirumotecan (SKB264) plus Tislelizumab Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 1

Top Sponsors

  • Zhejiang Provincial People's Hospital1
  • Shanghai Chest Hospital1

Indications

  • Cancer2
  • Advanced Thyroid Carcinoma1
  • Radioiodine Refractory Differentiated Thyroid Cancer1
  • Poorly Differentiated Thyroid Carcinoma1
  • Esophageal Squamous Cell Carcinoma1

Other2 trials

Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
Phase 2
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.